Omnia Molecular

Omnia Molecular designs and develops anti-infectives targeted at difficult-to-treat infections.

Omnia Molecular designs and develops antiinfectives targeted at difficult-to-treat infections. Omnia currently has programs targeting aaRS to develop pre-clinical drug candidates against infections caused by MRSA, Tuberculosis and Mycosis. Lead compounds are synthesized and optimized using a proprietary biotechnology platform and are proven effective in several biological assays. Final proof of concept is conducted in animal infection models. Thanks to Omnia's technology and design expertise, pre-clinical timelines and costs are reduced, and candidate compounds are substantially derisked in the pre-clinical phase. Lead compounds are partnered for co-development with pharma industry at pre-clinical proof-of-concept (validation in standard animal models of infection).